Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 2Neoplasms 2Colorectal Neoplasms 2Carcinoma 2Squamous Cell Carcinoma of Head and Neck 1Neoplasms, Glandular and Epithelial 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Castration Resistant Prostate Cancer 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

Bevacizumab 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neoplasms, Glandular and Epithelial × ALT-803 × Clear all
NCT07574541 2026-06-04

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

National Institutes of Health Clinical Center (CC)

Phase 2 Not yet recruiting
52 enrolled
Genitourinary

Adenocarcinoma, Carcinoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡